ResApp Health (ASX:RAP) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

RAP Aktienübersicht

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.

Über das Unternehmen

RAP grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Has less than 1 year of cash runway

Earnings have declined by 0.5% per year over past 5 years

Does not have meaningful revenue (A$4M)

Volatile share price over the past 3 months

ResApp Health Limited Wettbewerber

MedAdvisor

ASX:MDR

AU$275.3m

Volpara Health Technologies

ASX:VHT

AU$291.3m

Alcidion Group

ASX:ALC

AU$61.8m

Beamtree Holdings

ASX:BMT

AU$66.5m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für ResApp Health
Historische Aktienkurse
Aktueller Aktienkurs	AU$0.20
52-Wochen-Hoch	AU$0.21
52-Wochen-Tief	AU$0.048
Beta	-0.42
11 Monat Veränderung	7.90%
3 Monate Veränderung	17.14%
1 Jahr Veränderung	153.09%
33 Jahre Veränderung	2.50%
5 Jahre Veränderung	192.86%
Veränderung seit IPO	-96.25%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	RAP	AU Healthcare Services	AU Markt
7D	0%	5.5%	0.5%
1Y	153.1%	95.7%	9.9%

Rendite im Vergleich zur Industrie: RAP exceeded the Australian Healthcare Services industry which returned -22.6% over the past year.

Rendite vs. Markt: RAP exceeded the Australian Market which returned -8.2% over the past year.

Preisvolatilität

Is RAP's price volatile compared to industry and market?
RAP volatility
RAP Average Weekly Movement	17.6%
Healthcare Services Industry Average Movement	9.5%
Market Average Movement	8.3%
10% most volatile stocks in AU Market	15.9%
10% least volatile stocks in AU Market	3.2%

Stabiler Aktienkurs: RAP's share price has been volatile over the past 3 months.

Volatilität im Zeitverlauf: RAP's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2000	n/a	Tony Keating	www.resapphealth.com.au

ResApp Health Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von ResApp Health im Vergleich zum Marktanteil des Unternehmens?
RAP grundlegende Statistiken
Marktanteil	AU$176.24m
Gewinn(TTM)	-AU$7.10m
Umsatz(TTM)	AU$3.81m

46.3x

Kurs-Umsatz-Verhältnis

-24.8x

Kurs-Gewinn-Verhältnis

Ist RAP zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RAP Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$3.81m
Kosten der Einnahmen	AU$0
Bruttogewinn	AU$3.81m
Sonstige Ausgaben	AU$10.91m
Umsatz	-AU$7.10m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.0083
Bruttomarge	100.00%
Nettogewinnspanne	-186.19%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich RAP auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

RAP Aktienübersicht

Belohnungen

Risikoanalyse

ResApp Health Limited Wettbewerber

ASX:MDR

AU$275.3m

ASX:VHT

AU$291.3m

ASX:ALC

AU$61.8m

ASX:BMT

AU$66.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited (ASX:RAP).

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.009 loss in FY 2021)

ResApp Health Limited to Report Q4, 2022 Results on Jul 27, 2022

ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx

ResApp Health Limited Announces Results from Data Confirmation Study

No independent directors

Recent updates

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited (ASX:RAP).

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.009 loss in FY 2021)

ResApp Health Limited to Report Q4, 2022 Results on Jul 27, 2022

ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx

ResApp Health Limited Announces Results from Data Confirmation Study

No independent directors

No independent directors

ResApp Health Limited to Report Q3, 2022 Results on Apr 26, 2022

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ResApp Health Limited Completes Recruitment in its U.S. Covid-19 Clinical Study

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

ResApp Receives Regulatory Approvals for Cough Counter

ResApp Health Limited Completes COVID-19 Study Recruitment in India

ResApp Health Limited Receives Advanced and Overseas R&D Finding

ResApp Health Limited Receives Regulatory Approval in Indonesia

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Medgate Extends European ResAppDx Trial

Forecast breakeven moved forward to 2021

ResApp Health Limited Reports Recruited the First Participant in Its US-Based Clinical Study to Explore the Relationship Between Cough and SARS-Cov2 Infection

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

ResApp to Progress Clinical Study to Develop Covid-19 Smartphone-Based Screening Test

Medgate AG Commences ResApp Health Limited 's European ResAppDx Trial

Resapp Health Limited Achieves CE Mark for Wearable Device

ResApp Health Limited Provides an Update on its Two-Year, Non-Exclusive Software Licencing Agreement with Workplace Medicine Australia Ltd

ResApp Health Limited Announces Resignation of Stephen Hewitt-Dutton as Joint Company Secretary

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited Strengthens Patent Position in Europe

ResApp Health Limited to Report Q2, 2021 Results on Jan 29, 2021

Resapp Health Limited Appoints Mike Connell as Vice President, Commercial

ResApp Health Limited Launches SleepCheck

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

ResApp Health Limited Releases Version 2.3 of its ResAppDx Smartphone Application

ResApp Health Limited Appoints Stephen Hewitt-Dutton as Joint Company Secretary

ResApp Health Limited Signs Non-Exclusive, Two-Year Software Licensing Agreement with Workplace Medicine Australia Ltd

Medgate to Pilot ResAppDx for Telehealth Across Europe

ResApp Health Limited to Report Q1, 2021 Results on Oct 30, 2020

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited to Report Q4, 2020 Results on Jul 29, 2020

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

ResApp Health Limited's Grundlagenzusammenfassung

46.3x

-24.8x

Erträge &amp; Einnahmen

Erträge & Einnahmen